Neural substrate of quality of life in patients with schizophrenia: a magnetisation transfer imaging study

Catherine Faget-Agius, Laurent Boyer, Jonathan Wirsich, Jean-Philippe Ranjeva, Raphaelle Richieri, Elisabeth Soulier, Sylviane Confort-Gouny, Pascal Auquier, Maxime Guye, Christophe Lançon, Catherine Faget-Agius, Laurent Boyer, Jonathan Wirsich, Jean-Philippe Ranjeva, Raphaelle Richieri, Elisabeth Soulier, Sylviane Confort-Gouny, Pascal Auquier, Maxime Guye, Christophe Lançon

Abstract

The aim of this study was to investigate the neural substrate underlying quality of life (QoL) and to demonstrate the microstructural abnormalities associated with impaired QoL in a large sample of patients with schizophrenia, using magnetisation transfer imaging. A total of 81 right-handed men with a diagnosis of schizophrenia and 25 age- and sex-similar healthy controls were included and underwent a 3T MRI with magnetization transfer ratio (MTR) to detect microstructural abnormalities. Compared with healthy controls, patients with schizophrenia had grey matter (GM) decreased MTR values in the temporal lobe (BA21, BA37 and BA38), the bilateral insula, the occipital lobe (BA17, BA18 and BA19) and the cerebellum. Patients with impaired QoL had lower GM MTR values relative to patients with preserved QoL in the bilateral temporal pole (BA38), the bilateral insula, the secondary visual cortex (BA18), the vermis and the cerebellum. Significant correlations between MTR values and QoL scores (p < 0.005) were observed in the GM of patients in the right temporal pole (BA38), the bilateral insula, the vermis and the right cerebellum. Our study shows that QoL impairment in patients with schizophrenia is related to the microstructural changes in an extensive network, suggesting that QoL is a bio-psychosocial marker.

Trial registration: ClinicalTrials.gov NCT01295411.

Figures

Figure 1. Brain tissue MTR maps of…
Figure 1. Brain tissue MTR maps of patients compared to controls.
Brain regions with GM decrease in MTR values for patients with schizophrenia compared to controls.
Figure 2. Brain tissue MTR maps of…
Figure 2. Brain tissue MTR maps of patients with preserved QoL compared to controls (a), of patients with impaired QoL compared to controls (b), and of patients with impaired QoL compared to patients with preserved QoL (c).
Figure 3. Correlation between MTR values and…
Figure 3. Correlation between MTR values and S-QoL 18 index scores.
A low MTR value in the right cerebellum, vermis, temporal pole and bilateral insula was correlated with the S-Qol 18 index scores in patients with schizophrenia.

References

    1. McGrath J., Saha S., Chant D. & Welham J. Schizophrenia: A Concise Overview of Incidence, Prevalence, and Mortality. Epidemiol. Rev. 30, 67–76 (2008).
    1. Boyer L. et al. Measuring quality of life in patients with schizophrenia:an overview. Expert Rev. Pharmacoecon. Outcomes Res. 13, 343–349 (2013).
    1. Awad A. G., Voruganti L. N. & Heslegrave R. J. Measuring quality of life in patients with schizophrenia. PharmacoEconomics 11, 32–47 (1997).
    1. Lambert M., Karow A., Leucht S., Schimmelmann B. G. & Naber D. Remission in schizophrenia: validity, frequency, predictors, and patients’ perspective 5 years later. Dialogues Clin. Neurosci. 12, 393–407 (2010).
    1. Boyer L. et al. Quality of life is predictive of relapse in schizophrenia. BMC Psychiatry 13, 15 (2013).
    1. Awad A. G. & Voruganti L. N. P. Measuring quality of life in patients with schizophrenia: an update. PharmacoEconomics 30, 183–195 (2012).
    1. Boyer L. & Auquier P. The lack of impact of quality-of-life measures in schizophrenia: a shared responsibility? PharmacoEconomics 30, 531–532; author reply 532–533 (2012).
    1. Boyer L., Baumstarck K., Guedj E. & Auquier P. What’s wrong with quality-of-life measures? A philosophical reflection and insights from neuroimaging. Expert Rev. Pharmacoecon. Outcomes Res. 14, 767–769 (2014).
    1. Halyard M. Y., Frost M. H., Dueck A. & Sloan J. A. Is the use of QOL data really any different than other medical testing? Curr. Probl. Cancer 30, 261–271 (2006).
    1. Halyard M. Y., Frost M. H. & Dueck A. Integrating QOL assessments for clinical and research purposes. Curr. Probl. Cancer 30, 319–330 (2006).
    1. Gill T. M. & Feinstein A. R. A critical appraisal of the quality of quality-of-life measurements. JAMA 272, 619–626 (1994).
    1. Boyer L. et al. Functional involvement of superior temporal sulcus in quality of life of patients with schizophrenia. Psychiatry Res. 202, 155–160 (2012).
    1. Ubukata S. et al. Regional gray matter reduction correlates with subjective quality of life in schizophrenia. J. Psychiatr. Res. 47, 548–554 (2013).
    1. Higuchi Y. et al. Electrophysiological basis for the ability of olanzapine to improve verbal memory and functional outcome in patients with schizophrenia: a LORETA analysis of P300. Schizophr. Res. 101, 320–330 (2008).
    1. Pu S. et al. Association between subjective well-being and prefrontal function during a cognitive task in schizophrenia: a multi-channel near-infrared spectroscopy study. Schizophr. Res. 149, 180–185 (2013).
    1. Foong J. et al. Neuropathological abnormalities in schizophrenia: evidence from magnetization transfer imaging. Brain J. Neurol. 124, 882–892 (2001).
    1. Bagary M. S. et al. Gray and white matter brain abnormalities in first-episode schizophrenia inferred from magnetization transfer imaging. Arch. Gen. Psychiatry 60, 779–788 (2003).
    1. Ranjeva J.-P. et al. Local tissue damage assessed with statistical mapping analysis of brain magnetization transfer ratio: relationship with functional status of patients in the earliest stage of multiple sclerosis. AJNR Am. J. Neuroradiol. 26, 119–127 (2005).
    1. Price G. et al. Brain pathology in first-episode psychosis: magnetization transfer imaging provides additional information to MRI measurements of volume loss. NeuroImage 49, 185–192 (2010).
    1. Bohner G. et al. MTR abnormalities in subjects at ultra-high risk for schizophrenia and first-episode schizophrenic patients compared to healthy controls. Schizophr. Res. 137, 85–90 (2012).
    1. American Psychiatric Association. In Diagnostic and statistical manual of mental disorders, (4th edition, text revised), 343–399 (APA, 2000).
    1. First Michael B., Spitzer Robert L. & Gibbon Miriam W. J. B. Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient Edition. Biometrics Research, New York State Psychiatric Institute. (SCID-I/P) New York: Nov, 2002).
    1. Appelberg B., Tuisku K. & Joffe G. Is it worth while changing clinically stable schizophrenic out-patients with mild to moderate residual symptoms and/or side effects from conventional to atypical antipsychotics? A prospective, randomised study with olanzapine. Eur. Psychiatry J. Assoc. Eur. Psychiatr. 19, 516–518 (2004).
    1. CNIL. Act n°78-17 of 6 January 1978 on Data processing on information technology, data files and civil liberties. French Legislation.
    1. WMA. Declaration of Helsinki, ethical principles for medical research involving human subjects. (2008).
    1. Boyer L. et al. The development of the S-QoL 18: a shortened quality of life questionnaire for patients with schizophrenia. Schizophr. Res. 121, 241–250 (2010).
    1. Baumstarck K. et al. Self-reported quality of life measure is reliable and valid in adult patients suffering from schizophrenia with executive impairment. Schizophr. Res. 147, 58–67 (2013).
    1. Auquier P. et al. Toward meeting the needs of homeless people with schizophrenia: the validity of quality of life measurement. PloS One 8, e79677 (2013).
    1. Cramer J. A. et al. Quality of life in schizophrenia: a comparison of instruments. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. Schizophr. Bull. 26, 659–666 (2000).
    1. Baumstarck K. et al. Quantification of relevance of quality of life assessment for patients with cognitive impairment: the suitability indices. BMC Neurol. 14, 78 (2014).
    1. Kay S. R., Fiszbein A. & Opler L. A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 13, 261–276 (1987).
    1. Lançon C., Auquier P., Nayt G. & Reine G. Stability of the five-factor structure of the Positive and Negative Syndrome Scale (PANSS). Schizophr. Res. 42, 231–239 (2000).
    1. Talairach J. & Tournoux P. In Co-planar stereotaxic atlas of the human brain, Vol. 3 (eds Thieme-Stratton Corp) (1998).
    1. Brett M., Leff A. P., Rorden C. & Ashburner J. Spatial normalization of brain images with focal lesions using cost function masking. NeuroImage 14, 486–500 (2001).
    1. Gupta C. N. et al. Patterns of Gray Matter Abnormalities in Schizophrenia Based on an International Mega-analysis. Schizophr. Bull. 10.1093/schbul/sbu177 (2014).
    1. Goodkind M. et al. Identification of a Common Neurobiological Substrate for Mental Illness. JAMA Psychiatry 10.1001/jamapsychiatry.2014.2206 (2015).
    1. Honea R., Crow T. J., Passingham D. & Mackay C. E. Regional deficits in brain volume in schizophrenia: a meta-analysis of voxel-based morphometry studies. Am. J. Psychiatry 162, 2233–2245 (2005).
    1. Witthaus H. et al. Gray matter abnormalities in subjects at ultra-high risk for schizophrenia and first-episode schizophrenic patients compared to healthy controls. Psychiatry Res. 173, 163–169 (2009).
    1. Horn H. et al. Gray matter volume differences specific to formal thought disorder in schizophrenia. Psychiatry Res. 182, 183–186 (2010).
    1. Tang J. et al. Decrease in temporal gyrus gray matter volume in first-episode, early onset schizophrenia: an MRI study. PloS One 7, e40247 (2012).
    1. Wylie K. P. & Tregellas J. R. The role of the insula in schizophrenia. Schizophr. Res. 123, 93–104 (2010).
    1. Roper S. N., Lévesque M. F., Sutherling W. W. & Engel J. Surgical treatment of partial epilepsy arising from the insular cortex. Report of two cases. J. Neurosurg. 79, 266–269 (1993).
    1. Crespo-Facorro B. et al. Neural basis of novel and well-learned recognition memory in schizophrenia: a positron emission tomography study. Hum. Brain Mapp. 12, 219–231 (2001).
    1. Weinberger D. R., Torrey E. F. & Wyatt R. J. Cerebellar atrophy in chronic schizophrenia. Lancet 1, 718–719 (1979).
    1. Nopoulos P. C., Ceilley J. W., Gailis E. A. & Andreasen N. C. An MRI study of cerebellar vermis morphology in patients with schizophrenia: evidence in support of the cognitive dysmetria concept. Biol. Psychiatry 46, 703–711 (1999).
    1. Andreasen N. C. & Pierson R. The Role of the Cerebellum in Schizophrenia. Biol. Psychiatry 64, 81–88 (2008).
    1. Cascella N. G. et al. Gray-matter abnormalities in deficit schizophrenia. Schizophr. Res. 120, 63–70 (2010).
    1. Qiu L. et al. Neuroanatomical circuitry associated with exploratory eye movement in schizophrenia: a voxel-based morphometric study. PloS One 6, e25805 (2011).
    1. Kanaan R. et al. White matter microstructure in schizophrenia: effects of disorder, duration and medication. Br. J. Psychiatry J. Ment. Sci. 194, 236–242 (2009).
    1. Kurth F. et al. A link between the systems: functional differentiation and integration within the human insula revealed by meta-analysis. Brain structure & function. 214, 5–6 (2010).
    1. Palaniyappan L. & Liddle P. F. Does the salience network play a cardinal role in psychosis? An emerging hypothesis of insular dysfunction. J. Psychiatry Neurosci. JPN 37, 17–27 (2012).
    1. Adinoff B. Neurobiologic processes in drug reward and addiction. Harv. Rev. Psychiatry 12, 305–320 (2004).
    1. Goulden N. et al. The salience network is responsible for switching between the default mode network and the central executive network: replication from DCM. NeuroImage 99, 180–190 (2014).
    1. Jilka S. R. et al. Damage to the Salience Network and interactions with the Default Mode Network. J. Neurosci. Off. J. Soc. Neurosci. 34, 10798–10807 (2014).
    1. Sidlauskaite J. et al. Anticipatory processes in brain state switching - evidence from a novel cued-switching task implicating default mode and salience networks. NeuroImage 98, 359–365 (2014).
    1. Sridharan D., Levitin D. J. & Menon V. A critical role for the right fronto-insular cortex in switching between central-executive and default-mode networks. Proc. Natl. Acad. Sci. USA 105, 12569–12574 (2008).
    1. Andreasen N. C., Calarge C. A., Calage C. A. & O’Leary D. S. Theory of mind and schizophrenia: a positron emission tomography study of medication-free patients. Schizophr. Bull. 34, 708–719 (2008).
    1. Lysaker P. H. et al. Capacities for theory of mind, metacognition, and neurocognitive function are independently related to emotional recognition in schizophrenia. Psychiatry Res. 219, 79–85 (2014).
    1. Almashaikhi T. et al. Functional connectivity of insular efferences. Hum. Brain Mapp. 35, 5279–5294 (2014).
    1. Strata P. The Emotional Cerebellum. Cerebellum Lond. Engl. 10.1007/s12311-015-0649-9 (2015).
    1. Boyer L. et al. rTMS in fibromyalgia: a randomized trial evaluating QoL and its brain metabolic substrate. Neurology 82, 1231–1238 (2014).
    1. Chou C.-Y., Ma M.-C. & Yang T.-T. Determinants of subjective health-related quality of life (HRQoL) for patients with schizophrenia. Schizophr. Res. 154, 83–88 (2014).
    1. Fervaha G., Agid O., Takeuchi H., Foussias G. & Remington G. Clinical determinants of life satisfaction in chronic schizophrenia: data from the CATIE study. Schizophr. Res. 151, 203–208 (2013).
    1. Baumstarck K., Pelletier J., Boucekine M. & Auquier P. & MusiQoL study group. Predictors of quality of life in patients with relapsing-remitting multiple sclerosis: A 2-year longitudinal study. Rev. Neurol. (Paris) 171, 173–180 (2015).
    1. Maione P. et al. Pretreatment quality of life and functional status assessment significantly predict survival of elderly patients with advanced non-small-cell lung cancer receiving chemotherapy: a prognostic analysis of the multicenter Italian lung cancer in the elderly study. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 23, 6865–6872 (2005).
    1. Andreasen N. C. et al. Progressive brain change in schizophrenia: a prospective longitudinal study of first-episode schizophrenia. Biol. Psychiatry 70, 672–679 (2011).
    1. Andreasen N. C., Liu D., Ziebell S., Vora A. & Ho B.-C. Relapse duration, treatment intensity, and brain tissue loss in schizophrenia: a prospective longitudinal MRI study. Am. J. Psychiatry 170, 609–615 (2013).

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi